Herophilus, a leading biotechnology company developing neurotherapeutics to cure complex brain diseases, has brought on Scott Saywell as Chief Business Officer. Scott will serve on the executive leadership team overseeing the development of strategic partnerships that will enable the company to identify novel therapeutic targets and treatments for disorders including neurodevelopmental, psychiatric, and neurodegenerative diseases.
Scott brings to Herophilus over twenty-five years of experience in the biotech industry in a variety of roles, most recently as Vice President, Corporate Development and Strategy at Theravance Biopharma. Across several companies, Scott has completed transactions with a combined potential value of more than $2 billion. He also led the commercial planning activities for a first-in-class personalized cancer vaccine and helped establish one of the world’s first high-throughput DNA sequencing operations. Scott obtained his B.S. from the University of California, Los Angeles and his MBA from the Kellogg School of Management. See Full Press Release here